

Tagrisso® (osimertinib) – New Indication

- On April 18, 2017, the FDA approved <u>Astra Zeneca's Tagrisso® (osimertinib)</u>, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
 - Tagrisso is also indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
- According to the <u>American Cancer Society</u> lung cancer is the second most common cancer in both men and women. About 14% of all new cancers are lung cancers. Lung cancer is the leading cause of cancer death in the U.S, with an estimated 234,030 new diagnoses and 154,050 deaths for 2018.
- The new indication approval for Tagrisso was based on <u>FLAURA</u>, a clinical study of patients (n = 556) with EGFR exon 19 deletion or exon 21 L858R mutation-positive, metastatic NSCLC, who had not received previous systemic treatment for metastatic disease. Patients were randomized to Tagrisso, <u>Iressa®</u> (gefitinib), or <u>Tarceva®</u> (erlotinib) until disease progression or unacceptable toxicity. The efficacy outcomes were progression-free survival (PFS) and overall survival (OS).
 - The PFS was 18.9 months in the Tagrisso group vs. 10.2 months in the Iressa/Tarceva group (HR = 0.46, 95% CI: 0.37 to 0.57; p < 0.0001).
 - The objective response rate (ORR) was 80% in Tagrisso and 76% for the Iressa/Tarceva group (odds ratio = 1.27; 95% CI: 0.85 to 1.90; p = 0.24).
 - OS data were not mature at the time of the final PFS analysis.
 - The median duration of response was 17.2 months (95% CI: 13.8 to 22.0) with Tagrisso vs. 8.5 months (95% CI, 7.3 to 9.8) with Iressa/Tarceva.
 - The survival rate at 18 months was 83% (95% CI: 78 to 87) with Tagrisso and 71% (95% CI: 65 to 76) with Iressa/Tarceva (HR = 0.63; 95% CI: 0.45 to 0.88; p = 0.007).
- For both indications, the recommended dosage of Tagrisso is 80 mg once a day until disease progression or unacceptable toxicity.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.